Hayley Virgil

Lynparza, Zytiga and prednisone led to improved progression-free survival and response rates in patients with metastatic prostate cancer.

Researchers reported long-lasting responses and no new safety concerns in patients with relapsed/refractory follicular lymphoma during the 2023 ASH Annual Meeting and Exposition.

A low rate of high-grade blood-related side effects following treatment with induction Dara-KRd and consolidation double transplant was discovered in a trial for patients with high-risk, newly diagnosed multiple myeloma.

Survival outcomes and disparities for patients with blood cancers may depend on factors including insurance coverage, economic status and marital status.

Sugemalimab demonstrated safe and efficacious results when given after concurrent chemoradiation therapy or short-course chemoradiation therapy for patients with lung cancer.

The majority of patients with relapsed/refractory large B-cell lymphoma were alive between four and five years after being treated with axi-cel.

A panel of experts on the FDA’s Oncologic Drugs Advisory Committee voted that all future approvals of PI3K inhibitors to treat blood cancer be backed by randomized clinical trial data.

There were no major differences in survival when comparing intravenous and intraperitoneal chemotherapy plus Avastin in patients with advanced ovarian cancer, research shows.

The combination may offer patients with recurrent, platinum-agnostic ovarian cancer a more effective, non-platinum-based treatment option.

Patients with early triple-negative breast cancer receiving Imfinzi in addition to neoadjuvant chemotherapy saw increased survival rates and complete responses to treatment.

The use of Opdivo combined with the novel therapy relatlimab resulted in a significant improvement of progression-free survival compared to treatment with Opdivo, alone, in patients with previously untreated, unresectable or metastatic melanoma.